Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Knuth

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|February 4, 2014
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumorsVolker Lennerz, Stefanie Gross, Elisa Gallerani, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2006
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsElke Jäger, Julia Karbach, Sacha Gnjatic, et al.
Cancer Immunology, Immunotherapy : CII|November 21, 2007
Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patientsYuriy V Shebzukhov, Inna N Lavrik, Julia Karbach, et al.
Plos One|July 15, 2011
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerLotta von Boehmer, Lukas Keller, Ashkan Mortezavi, et al.
Oncology|November 17, 2010
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantationPanagiotis Samaras, Elefteri M Buset, Raffaele Daniele Siciliano, et al.
Oncology|June 13, 2012
Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trialChristoph Oehler, Karl Frei, Elisabeth J Rushing, et al.
Yeast (Chichester, England)|July 31, 2010
NY-ESO-1 protein glycosylated by yeast induces enhanced immune responsesAndreas Wadle, Axel Mischo, Sabine Strahl, et al.
International Journal of Cancer|February 1, 2014
Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancerSimon Laban, Djordje Atanackovic, Tim Luetkens, et al.
Case Reports in Oncology|October 29, 2013
Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent PatientSarah Pfrommer, Achim Weber, Philipp Dutkowski, et al.
Breast Cancer Research : BCR|September 20, 2005
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasGunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|February 4, 2014
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumorsVolker Lennerz, Stefanie Gross, Elisa Gallerani, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2006
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patientsElke Jäger, Julia Karbach, Sacha Gnjatic, et al.
Cancer Immunology, Immunotherapy : CII|November 21, 2007
Human tankyrases are aberrantly expressed in colon tumors and contain multiple epitopes that induce humoral and cellular immune responses in cancer patientsYuriy V Shebzukhov, Inna N Lavrik, Julia Karbach, et al.
Plos One|July 15, 2011
MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerLotta von Boehmer, Lukas Keller, Ashkan Mortezavi, et al.
Oncology|November 17, 2010
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantationPanagiotis Samaras, Elefteri M Buset, Raffaele Daniele Siciliano, et al.
Oncology|June 13, 2012
Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trialChristoph Oehler, Karl Frei, Elisabeth J Rushing, et al.
Yeast (Chichester, England)|July 31, 2010
NY-ESO-1 protein glycosylated by yeast induces enhanced immune responsesAndreas Wadle, Axel Mischo, Sabine Strahl, et al.
International Journal of Cancer|February 1, 2014
Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancerSimon Laban, Djordje Atanackovic, Tim Luetkens, et al.
Case Reports in Oncology|October 29, 2013
Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent PatientSarah Pfrommer, Achim Weber, Philipp Dutkowski, et al.
Breast Cancer Research : BCR|September 20, 2005
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasGunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, et al.
Pageof 13